Fusobacterium nucleatum, rectal cancer and radiotherapy.
Journal article
Mann EH. and Maughan TS., (2020), Ann Oncol
Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning
Journal article
VERRILL C. et al, (2020), Gut
A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol.
Journal article
Brown NF. et al, (2020), BMC Cancer, 20
Exploration of molecular signalling underpinning the DNA Damage Response Deficiency (DDRD) assay in Colorectal Cancer; Data from the S:CORT consortium (Stratification in COlorRecTal cancer)
Conference paper
Malla S. et al, (2019), BRITISH JOURNAL OF CANCER, 121, 3 - 3
Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
Journal article
Hague D. et al, (2019), Trials, 20
Mind the gap? The platform trial as a working environment.
Journal article
Morrell L. et al, (2019), Trials, 20
This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols.
Journal article
Schiavone F. et al, (2019), Trials, 20
Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses.
Journal article
Henderson R. et al, (2019), Oncotarget, 10, 3408 - 3423
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Journal article
Law PJ. et al, (2019), Nat Commun, 10
Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma.
Journal article
McGowan DR. et al, (2019), Eur J Cancer, 113, 87 - 95
Guidelines for using sigQC for systematic evaluation of gene signatures.
Journal article
Dhawan A. et al, (2019), Nat Protoc, 14, 1377 - 1400
Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2).
Journal article
Strauss VY. et al, (2019), BMC Cancer, 19
Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer.
Journal article
Gray V. et al, (2019), J Natl Cancer Inst
A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours
Conference paper
Wilson R. et al, (2018), EUROPEAN JOURNAL OF CANCER, 103, E140 - E141
Are All Colorectal Oligometastases Equal?
Conference paper
O'Cathail SM. et al, (2018), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102, E14 - E14
Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.
Journal article
Salem ME. et al, (2018), Eur J Cancer, 103, 205 - 213
KEAP1-NRF2 Pathway as a Modulator of Response to Radiation in Rectal Cancer
Conference paper
O'Cathail SM. et al, (2018), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 102, E191 - E192
SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): results of Stage 1 - the non-randomised dose-finding component
Conference paper
Mukherjee S. et al, (2018)
Safety and tumour hypoxia modifying effect of buparlisib with radiotherapy in NSCLC: a phase I dose escalation study
Conference paper
McGowan DR. et al, (2018)